Goossens F, Vanhoof G, De Meester I, Augustyns K, Borloo M, Tourwe D, Haemers A, Scharpé S
Laboratory for Medical Biochemistry, University of Antwerp, Belgium.
Eur J Biochem. 1997 Nov 15;250(1):177-83. doi: 10.1111/j.1432-1033.1997.00177.x.
The current study has been undertaken to develop new and biocompatible inhibitors for prolyl oligopeptidase, a highly specific endopeptidase, proposed to be involved, through its affinity for neuropeptides and kinins, in the processes of learning and memory and in the control of blood pressure. For in vitro evaluation of the inhibitors, human platelet prolyl oligopeptidase was purified to homogeneity and characterized. Northern blot analysis showed that mRNA coding for prolyl oligopeptidase was present in all tissues examined and only one transcript of 3.1 kb was detected. In addition to the human platelet enzyme, we also purified rat brain prolyl oligopeptidase, which proved to have the same characteristics as the human enzyme. In a series of tested peptides, bradykinin was found to be the best substrate. Based on this information, peptides bearing pseudopeptide bonds were generated and evaluated as inhibitors. The experiments clearly demonstrated that changes to the scissile peptide bond significantly decrease the affinity of prolyl oligopeptidase for the peptide derivatives. In our series of synthetic N-terminal blocked dipeptides, N-benzyloxycarbonyl-prolyl-3-fluoropyrrolidine was the most potent compound. Inhibition was reversible, but the inhibitor was bound tightly. Calculation of its Ki according to Henderson [Henderson, J. P. (1972) Biochem. J. 127, 321-333] yielded a value of 0.8 nM. This compound was not cytotoxic in a cell culture system and inhibited the purified prolyl oligopeptidase from rat as well as from human origin. In vivo evaluation in male Whistar rats showed no acute toxicity. 5 h after administration, the most profound decrease in prolyl oligopeptidase activity was found in the thymus, brain, and testis. This study demonstrates that N-benzyloxycarbonyl-prolyl-3-fluoropyrrolidine is a potent inhibitor and a promising compound suitable to investigate the physiologic function of the enzyme in vitro and in vivo.
开展本研究是为了开发脯氨酰寡肽酶的新型生物相容性抑制剂。脯氨酰寡肽酶是一种高度特异性的内肽酶,因其对神经肽和激肽具有亲和力,被认为参与学习和记忆过程以及血压控制。为了对抑制剂进行体外评估,将人血小板脯氨酰寡肽酶纯化至同质并进行表征。Northern印迹分析表明,在所检测的所有组织中均存在编码脯氨酰寡肽酶的mRNA,且仅检测到一种3.1 kb的转录本。除了人血小板酶外,我们还纯化了大鼠脑脯氨酰寡肽酶,结果证明其与人类酶具有相同的特性。在一系列测试肽中,发现缓激肽是最佳底物。基于此信息,生成了带有假肽键的肽并将其作为抑制剂进行评估。实验清楚地表明,对可裂解肽键的改变会显著降低脯氨酰寡肽酶对肽衍生物的亲和力。在我们的一系列合成N端封闭二肽中,N-苄氧羰基-脯氨酰-3-氟吡咯烷是最有效的化合物。抑制作用是可逆的,但抑制剂结合紧密。根据亨德森[亨德森,J.P.(1972年)《生物化学杂志》127卷,321 - 333页]计算其Ki值,结果为0.8 nM。该化合物在细胞培养系统中无细胞毒性,并且抑制来自大鼠以及人类来源的纯化脯氨酰寡肽酶。在雄性Wistar大鼠中进行的体内评估显示无急性毒性。给药5小时后,在胸腺、脑和睾丸中发现脯氨酰寡肽酶活性下降最为显著。本研究表明,N-苄氧羰基-脯氨酰-3-氟吡咯烷是一种有效的抑制剂,是一种有前景的化合物,适用于在体外和体内研究该酶的生理功能。